In a report released today, Christopher Raymond from Raymond James maintained a Buy rating on Biohaven Ltd., with a price target of $75.00. The company’s shares closed last Friday at $15.81.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Raymond covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, BioMarin Pharmaceutical, and Monopar Therapeutics Inc. According to TipRanks, Raymond has an average return of 2.7% and a 45.40% success rate on recommended stocks.
Biohaven Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $42.85.
BHVN market cap is currently $1.67B and has a P/E ratio of -2.06.
Read More on BHVN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
